← Back to Search

Calcium Channel Blocker

Verapamil Dilution for Peripheral Vasospasm

Q: Is enrollment for this clinical trial still a viable option?

<p>According to official records from clinicaltrials.gov, this medical study is currently recruiting patients for participation. The trial was first proposed on December 13th 2022 and the most recent updates were made on August 21st 2023.</p>

Q: What is the current cap on enrollees to this clinical research?

<p>Affirmative. Clinicaltrials.gov's data indicates that the clinical trial, which was posted in December 13th 2022, is actively seeking participants currently. The study needs to enlist 100 people from a single medical facility.</p>

Phase < 1

Recruiting

Led By Khalil Ibrahim, MD

Research Sponsored by University of Illinois at Chicago

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up approximately 30 minutes

Awards & highlights

Study Summary

This trial will compare the efficacy and safety of IA Verapamil diluted with normal saline to undiluted IA Nicardipine during a common heart procedure. Patients will be randomly assigned to one of two groups.

Eligible Conditions

Burning Pain
Peripheral Vasospasm
Pain

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ approximately 30 minutes

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~approximately 30 minutes

This trial's timeline: 3 weeks for screening, Varies for treatment, and approximately 30 minutes for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Pain After Intra-arterial Calcium Channel Blocker Administration

Pain Prior to Intra-arterial Calcium Channel Blocker Administration

Radial Artery Spasm

Trial Design

2Treatment groups

Active Control

Placebo Group

Group I: VerapamilActive Control1 Intervention

Intra-arterial Verapamil 5 mg (2mL) diluted with 8 mL of normal saline

Group II: NicardipinePlacebo Group1 Intervention

Intra-arterial Nicardipine 400 mcg undiluted (8mL)

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

University of Illinois at ChicagoLead Sponsor

607 Previous Clinical Trials

1,559,255 Total Patients Enrolled

Khalil Ibrahim, MDPrincipal InvestigatorUniversity of Illinois at Chicago

Media Library

Nicardipine (Calcium Channel Blocker) Clinical Trial Eligibility Overview. Trial Name: NCT05625503 — Phase < 1

Burning Pain Research Study Groups: Verapamil, Nicardipine

Burning Pain Clinical Trial 2023: Nicardipine Highlights & Side Effects. Trial Name: NCT05625503 — Phase < 1

Nicardipine (Calcium Channel Blocker) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05625503 — Phase < 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is enrollment for this clinical trial still a viable option?

"According to official records from clinicaltrials.gov, this medical study is currently recruiting patients for participation. The trial was first proposed on December 13th 2022 and the most recent updates were made on August 21st 2023."

Answered by AI

What is the current cap on enrollees to this clinical research?

"Affirmative. Clinicaltrials.gov's data indicates that the clinical trial, which was posted in December 13th 2022, is actively seeking participants currently. The study needs to enlist 100 people from a single medical facility."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Dilution of Verapamil During Intraarterial Administration

Khalil Ibrahim 2022. "Dilution of Verapamil During Intraarterial Administration". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05625503.